Up­dat­ed: Gilead col­lects 5th pri­or­i­ty re­view vouch­er as pub­lic ad­vo­ca­cy group urged the com­pa­ny to re­lin­quish it

Gilead re­cent­ly col­lect­ed its 5th pri­or­i­ty re­view vouch­er, this time for its megablock­buster Covid-19 drug remde­sivir, which brought in $1.5 bil­lion last quar­ter.

Many have …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER